Analysts’ Updated EPS Estimates for May, 17th (ACER, ACRX, ADVM, AIRI, AMTB, ANIP, APLS, AQMS, ARCT, CMPR)

Analysts’ updated eps estimates for Friday, May 17th:

Acer Therapeutics (NASDAQ:ACER) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “

AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.00 price target on the stock. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $9.00 target price on the stock. According to Zacks, “Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. “

Air Industries Group (NYSEAMERICAN:AIRI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Air Industries Group Inc. is engaged in designing and manufactureing flight critical products including flight safety parts, landing gear and components, arresting gear, flight controls, sheet metal fabrications and ground support equipment. The company also offers sheet metal fabrication of aerostructures, tube bending, welding and sub-contract machining services. It serves Prime Defense and Commercial aerospace manufacturers, through its subsidiaries. Air Industries Group Inc. is headquartered in Bay Shore, New York. “

Mercantil Bank (NASDAQ:AMTB) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Mercantil Bank Holding Corporation is a bank holding company that operates through its wholly-owned subsidiary bank, Amerant Bank N.A., including its investment and trust services subsidiaries, Amerant Investments Inc. and Amerant Trust N.A. It provides deposit, credit and wealth management services to individuals and businesses primarily in the United States. Mercantil Bank Holding Corporation is headquartered in Coral Gables, Florida. “

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “

Apellis Pharmaceuticals (NASDAQ:APLS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “

Aqua Metals (NASDAQ:AQMS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aqua Metals, Inc. is involved in the business of recycling lead through a process called AquaRefining(TM). Its AquaRefining process elements consists of non-toxic solvent that dissolves lead compounds and an electro-chemical process and electrolyze that converts the dissolved lead compounds into pure, primary grade lead. The Company’s AquaRefining process generates outputs consists of primary lead ingots; lead acid batteries grade lead alloy ingots; cleaned plastic chips, recovered from battery casings and sulphuric acid. Aqua Metals, Inc. is based in Oakland, California. “

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

Cimpress (NASDAQ:CMPR) had its buy rating reiterated by analysts at Barrington Research.

Restoration Robotics (NASDAQ:HAIR) had its hold rating reissued by analysts at Maxim Group.

Receive News & Ratings for Acer Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.